Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen

NCT00969033 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00969033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00969033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2009
Completion date
December 31, 2011
Enrollment
8 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer